Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,415 across all filing types
Latest filing 2010-11-05 Investor Presentation
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today that it will participate to the “Life Science Day”, a conference organized by NYSE-Euronext and France Biotech. This day will take pl
Investor Presentation Classification · 90% confidence The document is a press release dated November 5, 2010, announcing the company's participation in an upcoming investor conference ('Life Science Day') and listing future conferences. It provides company background, pipeline information, and contact details. This type of announcement, which informs the market about management's schedule for meeting investors and presenting strategy, aligns best with an Investor Presentation (IP) or a general announcement. Since it is not a formal financial report (like 10-K or IR) but rather an announcement about future engagement and strategy updates presented to investors, 'Investor Presentation (IP)' is the most fitting category, as these press releases often precede or summarize such events. However, given the content is purely an announcement of *participation* in an event rather than the presentation material itself, and it's a general corporate update, it could also be considered a Regulatory Filing (RNS) if no other category fits perfectly. Comparing the options, 'IP' covers the context of investor engagement and strategy updates, which is the core theme. It is not a Call Transcript (CT), Earnings Release (ER), or a formal report. I will classify it as Investor Presentation (IP) because the primary purpose is to inform the market about management's upcoming investor-facing activities and strategy discussions.
2010-11-05 English
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce son chiffre d’affaires pour la période du 1er janvier au 30 septembre 2010 et fait le point sur sa trésorerie
Earnings Release Classification · 99% confidence The document is titled 'INNATE PHARMA ANNONCE SON CHIFFRE D'AFFAIRES POUR LES NEUF PREMIERS MOIS DE L'ANNÉE 2010 ET FAIT LE POINT SUR SA TRESORERIE' (Innate Pharma announces its revenue for the first nine months of 2010 and provides an update on its cash position). It explicitly reports financial figures (revenue, cash position) for a nine-month period ending September 30, 2010. This content structure—a brief announcement focusing on key financial metrics for a period shorter than a full year—is characteristic of an Interim/Quarterly Report (IR). It is not a full Annual Report (10-K), nor is it merely an announcement of a report's publication (RPA), as it contains the actual summarized results. It is more detailed than a simple Earnings Release (ER) which usually focuses only on the highest-level results. 9M 2010
2010-11-05 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces its turnover for the first nine months of 2010 and updates on its cash situation
Earnings Release Classification · 99% confidence The document is titled "INNATE PHARMA ANNOUNCES ITS TURNOVER FOR THE FIRST NINE MONTHS OF 2010 AND UPDATES ON ITS CASH SITUATION". It provides key financial highlights (turnover, cash position) for a specific interim period (nine months ended September 30, 2010). This structure—announcing key results for a period shorter than a full year—is characteristic of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a formal presentation (IP). Since it is an initial announcement of period results, ER is the most appropriate classification. The document length (4898 chars) is consistent with a press release announcing results, not the full report itself. 9M 2010
2010-11-05 English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce aujourd’hui ses résultats semestriels au 30 juin 2010.
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the six-month period ending June 30, 2010, for Innate Pharma SA. It includes detailed financial statements (income statement, balance sheet data), analysis of operational results, research and development expenses, and management commentary on business trends. It is not a mere announcement or summary, as it contains substantive financial tables and detailed breakdowns of performance, fitting the definition of an Interim/Quarterly Report (IR). H1 2010
2010-08-31 French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces today its financial results for the first half of 2010.
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of 2010 (H1 2010). It contains detailed financial statements, including consolidated income statements, balance sheet items, cash flow analysis, and a breakdown of operating expenses by function and nature. It is not merely an announcement or a summary, as it provides substantive financial data and management's analysis of the results. Therefore, it is classified as an Interim/Quarterly Report. H1 2010
2010-08-31 English
Rapport financier semestriel au 30 juin 2010
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Rapport financier semestriel au 30 juin 2010' (Half-year financial report as of June 30, 2010) for Innate Pharma. It contains detailed financial statements, management discussion and analysis of results, and comparative data for the previous year. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2010
2010-08-31 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.